Supplementary Figure 5 from NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia

Abstract

<p>PDF file - 340KB, Supplementary figure 5. Combination of NADPH oxidases and BCR-ABL inhibitors progressively increases the proportion of sub-G1 phase cells.</p>